Abstract

Vilazodone is a partial agonist at the 5HT1A receptor and also inhibits serotonin reuptake; thus, it is referred to as a serotonin partial agonist/reuptake inhibitor (SPARI). Its effects at 5HT1A receptors are equal to or more potent than its effects at serotonin transporters. A prospective, randomized, active-controlled, parallel-group comparative open label study was conducted on total 92 patients of major depressive disorder at psychiatry OPD, meeting inclusion criteria. Diagnosis of patient as a patient of major depressive disorder was done by psychiatrist. A written informed consent from the patient or legal guardian of patient was taken after explaining nature and purpose of study in their own language. Patient information sheet containing all the necessary details of study was provided to patient. Patients who were selected for Vilazodone were found to have mean systolic BP of 113.00±15.45 mmHg, and patients belonging to Escitalopram were having 114.08±6.00 respectively. There was no statistically significant difference between two groups (P value 0.658). Patients who were selected for Vilazodone were found to have mean diastolic BP ± S.D. of 78.26±16.21, and patients belonging to Escitalopram were having 74.52±4.88 respectively. There was no statistically significant difference between two groups (P value 0.138).

Description